DuPont reimagined: A Deep Dive into the ‘New’ DuPont Post-Spinoff
Table of Contents
The impending November 1st split of DuPont marks a pivotal moment for investors, separating a focused industrial giant from its high-growth electronics division, Qnity Electronics. After an 18-month period of anticipation – what some analysts have termed “spin purgatory” – the restructured DuPont is poised to trade independently, offering a potentially undervalued opportunity for shareholders.
A Shift in Focus: Healthcare, Water, and Industrials
with the electronics business carved out, the “new” DuPont will concentrate its efforts on four core markets: healthcare, water, construction, and diversified industrials.Revenue distribution is projected to be approximately 25% healthcare, 24% construction, 22% water, 16% industrials/aerospace, printing and packaging, and 13% automotive. This strategic realignment signals a commitment to more stable, long-term growth sectors.
Healthcare: A $13 Billion Opportunity
DuPont’s healthcare division has demonstrated consistent organic sales growth in the mid-single digits, fueled by demand for medical packaging, devices, biopharmaceuticals, and protective garments. The company reports that over 90% of the top 25 U.S. medical device companies rely on DuPont technology for their most advanced products. This positions DuPont within a $13 billion addressable market, expanding at a rate exceeding overall GDP growth. Key trends driving this expansion include the increasing adoption of single-use systems, stringent occupational safety standards, demand for higher-performance materials, and the miniaturization of medical devices.
Water: A Critical Resource, and a Growing Market
DuPont is a leading force in the water industry, serving diverse end markets such as industrial water treatment, municipal and desalination projects, life sciences, and residential/commercial applications. Notably, the business plays a crucial role in semiconductor manufacturing.
From 2019 to 2025, mirroring the performance of its peer group, which includes 3M, Parker-Hannifin, Illinois Tool Works, ITT, Honeywell, and Dover. However, the company’s 2025 EBITDA margin of 23.6% slightly trails the peer average of 25.7%.
From a valuation perspective, DuPont currently trades at an Enterprise Value to EBITDA multiple of 11.4, a substantial discount compared to the peer average of 16.7. While acknowledging the margin gap, analysts believe the market’s discount is excessive. This undervaluation might potentially be partially attributed to ongoing liabilities related to PFAS “forever chemicals,” despite DuPont’s efforts to mitigate its legal exposure. The company’s complex history of mergers, acquisitions, and divestitures has also contributed to investor uncertainty.
Looking ahead,management projects a 3% to 4% CAGR in sales through 2028,driven by 5% organic growth in healthcare and water,and 2% growth in building and industrial markets. A 150 to 200 basis point improvement in operating EBITDA margin is targeted, fueled by net sales leverage, cost reductions from the spinoff, and productivity gains.Adjusted EPS growth is projected to reach 8% to 10% CAGR, with excess free cash flow potentially allocated to mergers and acquisitions or share buybacks.
In August, DuPont announced the divestiture of its Aramids business for $1.8 billion, encompassing the Kevlar and Nomex synthetic fiber brands. Management intends to deploy the proceeds to strengthen its healthcare and water divisions, further enhancing growth and margins.
The Valuation Debate and Investor Sentiment
Valuing the new dupont presents a challenge,differing from the more straightforward assessment of Qnity. While shedding a high-multiple asset like Qnity might suggest multiple compression, DuPont’s current valuation already reflects a notable discount to its peers. A more simplified structure and management team should be recognized, but determining a precise valuation remains complex.
After an extended period of “spin purgatory,” where investors delayed engagement pending the separation, the final stages of the breakup are now within reach. Jim Cramer’s Charitable Trust is long DD. The prevailing thesis remains that the spinoff will unlock value by allowing both new companies to trade at multiples more aligned with their respective peer groups.
